EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

Peak

efavirenz; lamivudine; tenofovir disoproxil fumarate

NDAORALTABLETPriority Review
Approved
Mar 2019
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].

External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers